TP53 and neoplasm: These subsets are associated with varied immune cell restrictions, altered angiogenesis, tumor microenvironment and poor survival [7, 39, 55]: (i) TP53 co-mutations activate the NF-κB pathway [56], increase IFNγ and PD-L1 expression [22] and promote an inflamed tumor immune microenvironment.